Literature DB >> 8200130

Induction of graft versus host disease in SCID mice by MRL/lpr cell transfer.

M Fraziano1, C Montesano, I Sammarco, S di Cesare, M C Caroleo, M Mattei, S Cannata, F Poccia, A Bellavia, A Salerno.   

Abstract

We have investigated the graft versus host (GvH) disease induced in immunodeficient SCID (H-2d) mice by intravenous (iv) or intraperitoneal (ip) transfer of either spleen or lymph node cells from autoimmune (MRL/lpr and MRL/++ mice, H-2k) and normal (CBA, H-2k) mice. Rapid and lethal GvH disease was observed when cells from MRL/lpr or MRL/++ were iv transferred into SCID mice, while spleen cells from nonautoimmune CBA donors were partially tolerized into SCID recipients and induced only lower levels of GvH reaction. No GvH reaction (complete tolerance) was observed when CBA lymph node cells were iv transferred into SCID recipients. In contrast, the ip injection of MRL/lpr or CBA spleen cells induces similar levels of GvH. The development of GvH disease in SCID recipients was due to the expansion of alloreactive CD8+ cells displaying significant cytotoxic activity against H-2d, but not against autologous targets. Also, a significant decrease of CD4/CD8 ratio was observed in the course of GvH caused by the iv transfer of cells from MRL/lpr mice. Altogether, these data support the hypothesis that lymphocytes from the MRL/lpr mice may escape tolerance in the GvH reaction.

Entities:  

Mesh:

Year:  1994        PMID: 8200130     DOI: 10.1006/clin.1994.1085

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  2 in total

1.  Immune therapeutic potential of stem cells from human supernumerary teeth.

Authors:  Y Makino; H Yamaza; K Akiyama; L Ma; Y Hoshino; K Nonaka; Y Terada; T Kukita; S Shi; T Yamaza
Journal:  J Dent Res       Date:  2013-05-22       Impact factor: 6.116

2.  Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders.

Authors:  D Watanabe; T Suda; H Hashimoto; S Nagata
Journal:  EMBO J       Date:  1995-01-03       Impact factor: 11.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.